Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Chinese adults with moderate to severe hidradenitis suppurativa (1-year, open-label)
CTR20260397Phase 4Active
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab in hidradenitis suppurativa (HS), sponsored by Novartis. Started Jun 2026; status: active.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on CTR20260397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260397.